PUBLICATIONS

PanCareSurPass is an EU-funded project looking at how to more widely implement the digital Survivorship Passport (SurPass) to improve survivorship care for survivors of childhood and adolescent cancer in Europe. PanCareSurPass will develop, test and implement the SurPass in participating countries and will develop material to support implementation in other countries

Title Authors Link PLAIN summary PDF
Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study van den Oever S et al. J Cancer Surviv 18, 928–940 (2024). https://doi.org/10.1007/s11764-023-01335-y PLAIN summary PDF
Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study de Beijer IAE et al. J Cancer Surviv (2023).
https://doi.org/10.1007/s11764-023-01498-8
PLAIN summary PDF
European recommendations for short-term surveillance of health problems in childhood, adolescent and young adult cancer survivors from the end of treatment to 5 years after diagnosis: a PanCare guideline de Beijer IAE et al. J Cancer Surviv (2023).
https://doi.org/10.1007/s11764-023-01493-z
PLAIN summary PDF
Scaling up and implementing the digital Survivorship Passport tool in routine clinical care – The European multidisciplinary PanCareSurPass project Filbert AL et al. Eur. J. Cancer 2024 march 17;202;114029
https://doi.org/10.1016/j.ejca.2024.114029
Factors Influencing Implementation of the Survivorship Passport: The IT Perspective Chronaki C et al. Stud Health Technol Inform. 2022 May 16;293:161-168. https://doi.org/10.3233/SHTI220363 PDF

PanCareFollowUp is an EU-funded project looking at how to best deliver survivorship care to survivors of childhood and adolescent cancer in Europe. The aim of PanCareFollowUp is to deliver care according to recently developed guidelines using an innovative model for person centred care that empowers survivors and supports self-management.

Title Authors Link PLAIN language summary PDF
Barriers, facilitators, and other factors associated with health behaviors in childhood, adolescent, and young adult cancer survivors: A systematic review de Beijer et al. Cancer Medicine 2024, 13(12):e7361. https://doi.org/10.1002/cam4.7361 coming soon PDF
Healthcare providers’ expected barriers and facilitators to the implementation of person‐centered long‐term follow‐up care for childhood cancer survivors: A PanCareFollowUp study Breij et al. Cancer Medicine 2024, 13(20), e70225. https://doi.org/10.1002/cam4.70225 coming soon PDF
Perceived barriers and facilitators to health behaviors in European childhood cancer survivors Bouwman E et al. Cancer Medicine 2023, 12(11): 12035-12959
https://doi.org/10.1002/cam4.5911
PLAIN summary PDF
Healthcare professionals’ perceived barriers and facilitators of health behavior support provision: A qualitative study Bouwman E et al. Cancer Medicine. 2023;12:7414–7426.
https://doi.org/10.1002/cam4.5445
PLAIN summary PDF
Person-centred online lifestyle coaching in childhood, adolescent, and young adult cancer survivors: protocol of the multicentre PanCareFollowUp lifestyle intervention feasibility study Bouwman E et al. Pilot and Feasibility Studies (2022) 8:260
https://doi.org/10.1186/s40814-022-01221-x
PLAIN summary PDF
Evaluating the feasibility, effectiveness and costs of implementing person-centred follow-up care for childhood cancer survivors in four European countries: the PanCareFollowUp Care prospective cohort study protocol van Kalsbeek RJ et al. BMJ Open 2022;12:e063134.
https://doi.org/10.1136/bmjopen-2022-063134
PLAIN summary PDF
The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer van Kalsbeek RJ et al. European Journal of Cancer 162; Feb 2022; 34 – 44
https://doi.org/10.1016/j.ejca.2021.10.035
PLAIN summary PDF
European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer van Kalsbeek RJ et al. European Journal of Cancer 154; Sep 2021; 316 – 328
https://doi.org/10.1016/j.ejca.2021.06.004
PLAIN summary PDF
The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers van Kalsbeek RJ et al. European Journal of Cancer 153; Aug 2021; 74 – 85
https://doi.org/10.1016/j.ejca.2021.05.030
PLAIN summary PDF

PanCareLIFE was a 5-year (2013-8) EU Framework 7 Programme in the Health Theme that studied the impact of treatment regimes on the long-term health of childhood cancer survivors. Specifically, PanCareLIFE evaluated the risks of impairments in female fertility, in hearing, and in quality of life. PanCareLIFE also developed two guidelines for fertility preservation, and will disseminate widely the results from this project. Below an overview of publications that were made within the PanCareLIFE project.

Title Authors Link PDF
Genetic variation in gonadal impairment in female survivors of childhood cancer: design of a PanCareLIFE study. van der Kooi ALF et al. BMC Cancer 18, 930.
https://doi.org/10.1186/s12885-018-4834-3
PDF
PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity, and health related quality of life after cancer occurring among children and adolescents. Byrne J et al. Eur J Cancer 103, 227-237, 2018.
https://doi.org/10.1016/j.ejca.2018.08.007
 
Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). van den Berg M et al. JMIR Res Protoc 7, e10824, 2018.
https://doi.org/10.2196%2F10824
 
Genetic determinants of ototoxicity during and after childhood cancer treatment: protocol for the PanCareLIFE study. Clemens E et al. JMIR Res Protoc 8, e11868, 2019.
https://doi.org/10.2196%2F11868
 
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Clemens E et al. Pharmacogenomics J 20, 294–305, 2020.
https://doi.org/10.1038/s41397-019-0113-1
 
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Langer T et al. Data in Brief 32:106227, 2020.
https://doi.org/10.1016/j.dib.2020.106227
PDF
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. Langer T et al. Eur J Cancer. 138, 212-224, 2020.
https://doi.org/10.1016/j.ejca.2020.07.019
 
Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function, van der Kooi ALF et al. Human Reproduction deaa342, 2021.
https://doi.org/10.1093/humrep/deaa342.
 
Health-related quality of life in European childhood cancer survivors: protocol for a study within PanCareLIFE . Calaminus G et al. JMIR Res Protoc 2021, 10: e21851
https://doi.org/10.2196/21851
 
Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). van den Berg H et al. Human Reproduction 0:1–13. 2021.
https://doi.org/10.1093/humrep/deab035
PDF
Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Mulder RL et al. The Lancet Oncology 22, e45 – e56, 2021.
https://doi.org/10.1016/S1470-2045(20)30594-5
 
Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Mulder RL et al. The Lancet Oncology 22, e57 – e67, 2021.
https://doi.org/10.1016/S1470-2045(20)30582-9
 
Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Mulder RL et al. The Lancet Oncology 22, e68 – e80, 2021.
https://doi.org/10.1016/S1470-2045(20)30595-7
 
Managing a pan-European consortium on late effects among long-term survivors of childhood and adolescent cancer – the PanCareLIFE project. Kaatsch P et al. Int J Environ Res Public Health 2021, 18, 3918.
https://doi.org/10.3390/ijerph18083918.
 
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. Meijer AJM et al. NPJ Precision Oncology; 5:64: February 2021.
https://doi.org/10.1038/s41698-021-00178-z
PDF
Fertility-Related Wishes and Concerns of Adolescent Cancer Patients and Their Parents. Korte E et al. J Adolesc Young Adult Oncol. 2020 Feb;9(1):55-62.
https://doi.org/10.1089/jayao.2019.0064
 
Fertility education for adolescent cancer patients: Gaps in current clinical practice in Europe. Korte E et al. Eur J Cancer Care 2020 Sep. Sep;29(5):e13279.
https://doi.org/10.1111/ecc.13279
PDF
Fertility knowledge and associated empowerment following an educational intervention for adolescent cancer patients. Borgmann-Staudt A et al. Psychooncology. 2019 Nov;28(11):2218-2225.
https://doi.org/10.1002/pon.5210
 
Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries. Balcerek M et al. Eur J Pediatr. 2020 Jan;179(1):51-60.
https://doi.org/10.1007/s00431-019-03459-9
 
PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity, and health related quality of life after cancer occurring among children and adolescents. Byrne J et al. Eur J Cancer 103, 227-237, 2018.
https://doi.org/10.1016/j.ejca.2018.08.007
PDF
Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). van den Berg M et al. JMIR Res Protoc 7, e10824, 2018.
http://doi.org/10.2196/10824
PDF
Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers Weiss A et al. Qual Life Res 28, 515–521 (2019).
https://doi.org/10.1007/s11136-018-2021-2
 
Europäische PanCare-Studien zu Spätfolgen nach Krebs im Kindes- und Jugendalter Grabow D et al. Onkologe 24, 754–759 (2018).
https://doi.org/10.1007/s00761-018-0449-1
 
The influence of genetic variation on late toxicities in childhood cancer survivors Clemens E et al. Critical Reviews in Oncology / Hematology 126 (2018) 154–167
https://doi.org/10.1016/j.critrevonc.2018.04.001
PDF
Audiological monitoring in Swiss childhood cancer patients Weiss A et al. Pediatric Blood & Cancer, 10.1002/pbc.26877, 65, 3, (2017).
https://doi.org/10.1002/pbc.26877
 
Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors Clemens E et al. Pediatric Hematology and Oncology, 34(2), 120–129.
https://doi.org/10.1080/08880018.2017.1323985
PDF
Socio-demographic impact of platinum-induced ototoxicity in long-term survivors of childhood cancer Clemens E et al. Curr Pediatr Res 2017; 21 (3): 470-479
https://www.researchgate.net/publication/325170052_Socio-demographic_impact_of_platinum-induced_ototoxicity_in_long-term_survivors_of_childhood_cancer
PDF
Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study Weiss A et al.

PLoS ONE 12 (3): e0174479.

https://doi.org/10.1371/journal. pone.0174479

PDF
Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study Clemens et al.

Eur J Cancer 2016 69:77-85

https://doi.org/10.1016/j.ejca.2016.09.023

 
Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss Van der Kooi ALF et al.

Hum Reprod 2017 32:193-200

https://doi.org/10.1093/humrep/dew278

PDF
Fertility preservation in children, adolescents and young adults with cancer: Quality of clinical practice guidelines and variations in recommendations Font-Gonzalez A et al. Cancer 2016: Cancer 2016 122(14):2216-23
https://doi.org/10.1002/cncr.30047
PDF

PanCareSurFup (PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies) is a consortium of 16 European institutions in 11 countries, funded by the 7th Framework Programme of the EC, and carried out research studies into late effects of treatment for cancer, established guidelines for follow-up, and disseminated the results and provided training and workshops for stakeholders.

Title Authors Link PDF
Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. Michel G et al. J Cancer Surviv. 2019 Oct;13(5):759-772.
https://doi.org/10.1007/s11764-019-00795-5
Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Clement SC et al. Cancer Treat Rev. 2018 Feb;63:28-39.
https://doi.org/10.1016/j.ctrv.2017.11.005
The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer. yrne J et al. Eur J Cancer. 2018 Nov;103:238-248.
https://doi.org/10.1016/j.ejca.2018.08.017
Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Skinner R et al. Lancet Oncol. 2017 Feb;18(2):e75-e90.
https://doi.org/10.1016/S1470-2045(17)30026-8
Increased risk of cardiac ischaemia in a pan-European cohort of 36 205 childhood cancer survivors: a PanCareSurFup study. Feijen EAM et al. Heart. 2021 Jan;107(1):33-40.
https://doi.org/10.1136/heartjnl-2020-316655
PDF
The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries. Grabow D et al. Eur J Epidemiol. 2018 Mar;33(3):335-349.
https://doi.org/10.1007/s10654-018-0370-3
PDF
Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. van Dorp W et al. J Clin Oncol. 2016 Oct 1;34(28):3440-50.
https://doi.org/10.1200/JCO.2015.64.3288
PDF
Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study. Reulen RC et al. Gut. 2020 Nov 2:gutjnl-2020-322237.
https://doi.org/10.1136/gutjnl-2020-322237
PDF
Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. Allodji RS et al. Eur J Cancer. 2019 Aug;117:71-83
https://doi.org/10.1016/j.ejca.2019.05.013
Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFup. Feijen EA et al. PLoS One. 2016 Sep 19;11(9):e0162778.
https://doi.org/10.1371/journal.pone.0162778
PDF
Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort. Wang Y et al. Eur J Cancer. 2022 Apr;165:27-47.
https://doi.org/10.1016/j.ejca.2022.01.001
Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium. Byrne J et al. Int J Cancer. 2022 Feb 1;150(3):406-419.
https://doi.org/10.1002/ijc.33817
PDF
The ‘Survivorship Passport’ for childhood cancer survivors. Haupt R et al. Eur J Cancer. 2018 Oct;102:69-81.
https://doi.org/10.1016/j.ejca.2018.07.006
PDF
The views of European clinicians on guidelines for long-term follow-up of childhood cancer survivors. Brown MC et al. Pediatr Blood Cancer. 2015 Feb;62(2):322-328.
https://doi.org/10.1002/pbc.25310
PDF
Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe. Bright CJ et al. J Natl Cancer Inst. 2018 Jun 1;110(6):649-660.
https://doi.org/10.1093/jnci/djx235
PDF
Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe. Fidler MM et al. J Natl Cancer Inst. 2018 Feb 1;110(2).
https://doi.org/10.1093/jnci/djx165
PDF
The views of European clinicians on guidelines for long-term follow-up of childhood cancer survivors. Brown MC et al. Pediatr Blood Cancer. 2015 Feb;62(2):322-328.
https://doi.org/10.1002/pbc.25310
PDF
Recommendations for Cardiomyopathy Surveillance for Survivors of Childhood Cancer: A Report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Armenian SH et al. Lancet Oncology 2015; 16: e123-136.
https://doi.org/10.1016/s1470-2045(14)70409-7
PDF
The European Experience of Establishing Guidelines for Surveillance of the Childhood Cancer Survivor, in Handbook of Long Term Care of the Childhood Cancer Survivor. Skinner R et al.
In Handbook of Long-Term Care of the Childhood Cancer Survivor; Mucci, G., Torno, L., Eds.;
Springer: New York, NY, USA, 2015; pp. 25–35

https://doi.org/10.1007/978-1-4899-7584-3_3

Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. Hjorth L et al. Eur J Cancer, 2015. 51(10): 1203-1211.
https://doi.org/10.1016/j.ejca.2015.04.002
PDF
Surveillance of late effects by treatment: the European experience. Skinner R et al. Handbook of Long Term Care of the Childhood Cancer Survivor”, ed GA Mucci.
A New Method to Facilitate Valid and Consistent Grading Cardiac Events in Childhood Cancer Survivors Using Medical Records Feijen EL et al. PLoS One. 2014; 9(7): e100432.
https://doi.org/10.1371/journal.pone.0100432
PDF
Risk of second bone sarcoma following childhood cancer: role of radiation therapy treatment. Schwartz B et al. Radiat Environ Biophys, 2014. 53(2): 381-90.
https://doi.org/10.1007/s00411-013-0510-9
PDF
REPORT: Handbook for guideline development; collaboration between International Guideline Harmonization Group, PanCareSurFup and Cochrane Childhood Cancer Group. Mulder RL et al. PDF
A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Kremer LC et al. Pediatr Blood Cancer, 2013. 60(4): 543-9.
https://doi.org/10.1002/pbc.24445
PDF
Developing international consensus for late effects screening and guidance. Skinner R et al. Current Opinion in Supportive and Palliative Care 7(3):p 303-308, September 2013.
https://doi.org/10.1097/SPC.0b013e328363a607
Health problems in survivors of childhood cancer: the need for international collaboration in long-term follow-up care Mulder RL et al. Future Oncol. 2013 Nov;9(11):1667-70
https://doi.org/10.2217/fon.13.107
PDF
Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Mulder RL et al. Lancet Oncol, 2013. 14(13): e621-9.
https://doi.org/10.1016/S1470-2045(13)70303-6
PDF
Transitional care of a childhood cancer survivor to adult services, facilitating the process of individual access to different models Frey E et al. Curr Opin Support Palliat Care. 2013 Sep;7(3):309-13.
https://doi.org/10.1097/SPC.0b013e32836484bb
Cohort profile: The Swiss Childhood Cancer Survivor Study. Kuehni CE et al. Int J Epidemiol,2012. 41(6): 1553-1564.
https://doi.org/10.1093/ije/dyr142
PDF
Total heart volume as a function of clinical and anthropometric parameters in a population of external beam radiation therapy patients Badouna AN et al. Phys Med Biol. 2012 Jan 21;57(2):473-84
https://doi.org/10.1088/0031-9155/57/2/473